Associated Papers
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
41022739 (PubMed )
Supplement: 41467_2025_63528_MOESM7_ESM.xlsx › Sheet1
Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1.
Wen J et al.
Fundamental Research, 2023
Transcription-independent functions of p53 in DNA repair pathway selection.
Wang YH et al.
Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology, 2023
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
35043155 (PubMed )
Supplement: supplementary_table_s1_bbab524.xlsx › S1B._Negative_Set
Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
Cipriano NM et al.
Breast Cancer (tokyo, Japan), 2019
BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency.
Yılmaz NK et al.
Journal of the Turkish German Gynecological Association, 2016
The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain.
Laptenko O et al.
Molecular Cell, 2015
The nucleolar protein Myb-binding protein 1A (MYBBP1A) enhances p53 tetramerization and acetylation in response to nucleolar disruption.
Ono W et al.
The Journal of Biological Chemistry, 2014
Kinetics of repression by modified p53 on the PDGF beta-receptor promoter.
Yang W et al.
International Journal of Cancer, 2008
Select a paper to view details